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Abstract: Angiogenesis, the process of forming new blood vessels, is crucial in the physiological
response to ischemia, though it can be detrimental as part of inflammation and tumorigenesis.
We have previously shown that high-density lipoproteins (HDL) modulate angiogenesis in a
context-specific manner via distinct classical signalling pathways, enhancing hypoxia-induced
angiogenesis while suppressing inflammatory-driven angiogenesis. Whether additional novel targets
exist to account for these effects are unknown. A microarray approach identified two novel genes,
cyclic-adenosine-monophosphate-response-element-binding protein 3 regulatory factor (CREBRF)
and tripartite motif-containing protein 2 (TRIM2) that were upregulated by reconstituted HDL (rHDL).
We measured CREBRF and TRIM2 expression in human coronary artery endothelial cells following
incubation with rHDL and exposure to either hypoxia or an inflammatory stimulus. We found that
CREBRF and TRIM2 mRNA were significantly upregulated by rHDL, particularly in response to its
phospholipid component 1-palmitoyl-2-linoleoyl-phosphatidylcholine, however, protein expression
was not significantly altered. Knockdown of TRIM2 impaired endothelial cell tubulogenesis in vitro
in both hypoxia and inflammation, implying a necessary role in angiogenesis. Furthermore, TRIM2
knockdown attenuated rHDL-induced tubule formation in hypoxia, suggesting that it is important
in mediating the pro-angiogenic action of rHDL. Our study has implications for understanding the
regulation of angiogenesis in both of these pathophysiological contexts by HDL.
Keywords: angiogenesis; high-density lipoproteins; hypoxia; inflammation; TRIM2; CREBRF
1. Introduction
Angiogenesis, the process in which new blood vessels are formed from pre-existing vessels,
is vital in many physiological contexts, such as during wound healing and as an adaptive response
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to tissue ischemia [1]. Angiogenesis, however, also plays a key role in many pathological conditions.
Excessive angiogenesis stimulated by inflammation can accelerate the development of atherosclerotic
plaque by providing additional conduits for the delivery of inflammatory cells and cytokines [2].
Dysregulated angiogenesis can also promote the growth, survival and metastasis of tumors [3,4].
Angiogenesis-associated pathologies such as cardiovascular disease and cancer contribute significantly
to mortality and morbidity rates worldwide [5,6]. Any agent capable of differentially modulating
angiogenesis in a context-specific manner would conceivably be of great therapeutic value.
In addition to its well-recognized athero-protective, anti-inflammatory, anti-oxidative and
anti-thrombotic properties [7], a growing body of evidence suggests that high-density lipoproteins
(HDL) are able to regulate angiogenesis in a multifunctional manner depending on the
pathophysiological context [8]. Treatment of human coronary artery endothelial cells (HCAECs)
with reconstituted HDL (rHDL), composed of the main apolipoprotein A-I (apoA-I) constituent
of native HDL, complexed with the phospholipid 1-palmitoyl-2-linoleoyl-phosphatidylcholine
(PLPC), significantly increased tubulogenesis, proliferation and migration of HCAECs in response
to hypoxia [9,10]. These effects were attenuated when rHDL-treated HCAECs were exposed to the
inflammatory cytokine, tumor necrosis factor α (TNFα) [9], suggesting a dichotomous role for HDL
in angiogenesis. In an in vivo setting, intravenous delivery of rHDL or apoA-I in murine models of
hindlimb ischemia (HLI) resulted in accelerated recovery of blood perfusion and increased capillary
density in the ischemic hindlimbs [9,11–13]. Similar results were seen in a rabbit model of HLI following
treatment with des-fluoro-anacetrapib, an inhibitor of cholesteryl ester transfer protein (CETP) which
raises HDL levels [14]. Conversely, intravenous apoA-I impaired the inflammatory response that
was induced by a silicon cuff placed around the femoral arteries of mice, reducing the formation of
adventitial neovessels and the infiltration of macrophages [9]. Similarly, in a rabbit carotid cuff model,
infusions of rHDL or apoA-I reduced the generation of vascular reactive oxygen species, leukocyte
infiltration and expression of inflammatory chemokines [15]. These studies highlight that HDL is able
to enhance hypoxia-induced angiogenesis while inhibiting inflammation-driven angiogenesis.
Many classically known angiogenic pathways and mediators have been implicated downstream
of HDL. In hypoxia, HDL augments angiogenesis by interacting with its receptor scavenger receptor
class B type I (SR-BI), activating the phosphatidylinositol-3-kinase (PI3K)/Akt pathway. This leads to
modulation of the transcription factor hypoxia-inducible factor-1α (HIF-1α) and in turn upregulates
the expression of vascular endothelial growth factor (VEGF) and chemokine CXCL12, both potent
stimulators of angiogenesis [9,10]. Meanwhile in response to inflammation, HDL is able to inhibit
the key transcription factor nuclear factor kappa B (NFκB) thereby reducing nucleic p65 (the active
subunit of NFκB) and various mediators such as TNFα, monocyte chemoattractant protein-1 (MCP-1),
vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule 1 (ICAM-1) which
crucially recruit macrophages to sustain the inflammatory response [16–18]. As opposed to hypoxia,
the expression of HIF-1α, VEGF and its receptor, VEGF receptor 2 (VEGFR2), are inhibited by HDL in
inflammation [9], leading to suppression of angiogenesis where it can be detrimental.
Whether HDL’s effects on angiogenesis are mediated through novel and yet uncharacterized
molecular pathways remains unknown, but it is clear that further elucidation of HDL’s mechanistic
targets is needed to facilitate potential clinical translation of HDL-related therapies in diseases
associated with angiogenesis. In this study, we aimed to explore the possibility of novel genes
that could be involved in the regulation of angiogenesis by HDL under both hypoxic and inflammatory
conditions. We undertook a microarray approach and identified, for the first time, two genes
cyclic-adenosine-monophosphate-response-element-binding protein 3 regulatory factor (CREBRF) and
tripartite motif-containing protein 2 (TRIM2), that were upregulated by rHDL under both angiogenic
conditions. We further investigated the expression profiles of these genes in HCAECs as triggered by
rHDL and its individual components apoA-I and PLPC, showing the latter to be particularly important
in promoting the transcription of both genes. Moreover, we demonstrate that knockdown of TRIM2
impairs tubulogenesis in vitro, highlighting a putative role for this gene in angiogenesis, and more
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broadly in vascular biology, that has not been previously characterized. Finally, TRIM2 knockdown
attenuated the ability of rHDL to augment tubule formation in hypoxia, suggesting that it is important
in mediating the pro-angiogenic action of rHDL in physiological conditions.
2. Results
2.1. CREBRF and TRIM2 Are Novel Targets of rHDL in Response to Angiogenic Stimuli
A microarray study using human microvascular endothelial cells (HMVECs) was undertaken to
investigate potential gene targets of rHDL in hypoxia and inflammation. Over 20,000 genes mapped
through RefSeq or via UniGene annotation were screened using the GeneChip® PrimeViewTM Human
Gene Expression Arrays. In response to hypoxia stimulation, rHDL significantly regulated 1452 genes
(Supplementary Table S1) while 1256 genes were differentially regulated by rHDL following an
inflammatory stimulus (Supplementary Table S2). Further analysis was then undertaken to identify
the top differentially expressed genes with no established role in angiogenesis that were specifically
regulated by rHDL in response to angiogenic stimuli. Eight genes demonstrated significant changes
in expression when treated with rHDL under hypoxic conditions (Figure 1A). Four genes were
significantly upregulated (CREBRF, TRIM2, DGKG and FADS1) while four were downregulated (CELF2,
GPR126, NEK7 and ITPR2). Conversely, twelve genes exhibited significant changes in expression
when HMVECs were treated with rHDL then exposed to the inflammatory cytokine TNFα. Seven
genes were upregulated (CREBRF, TRIM2, FAM102A, GFTP1, DDIT4, NR1D2 and SLC6A6) while
five were downregulated (TOX, MEX3A, CBX5, MYBL1 and RECK). Two genes, CREBRF and TRIM2,
were significantly upregulated by rHDL in response to both hypoxia and inflammation.
Figure 1. Cont.
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Figure 1. CREBRF and TRIM2 mRNA expression in human coronary artery endothelial cells (HCAECs)
in response to treatment with reconstituted high-density lipoproteins (rHDL) or phosphate-buffered
saline (PBS, vehicle control) in hypoxia and inflammation. (A) A microarray approach identified genes
whose expression was increased (↑) or decreased (↓) in response to rHDL in hypoxia and inflammation.
(B) CREBRF mRNA and (C) TRIM2 mRNA in PBS- and rHDL-treated cells exposed to normoxia
and hypoxia; (D) CREBRF mRNA and (E) TRIM2 mRNA in PBS- and rHDL-treated cells with and
without tumor necrosis factor alpha (TNFα) stimulation. mRNA expression was measured by real-time
quantitative polymerase chain reaction (qPCR). Results are mean ± SEM. * p < 0.05, *** p < 0.001,
**** p < 0.0001 by two-way ANOVA with post hoc analysis using Bonferroni’s multiple comparisons
test. ˆ p < 0.05, ˆˆˆ p < 0.001, ˆˆˆˆ p < 0.0001 by unpaired two-tailed t-test.
2.2. rHDL Modulates CREBRF and TRIM2 Expression in Human Coronary Artery Endothelial Cells
(HCAECs) under Hypoxia and Inflammation
HCAECs pre-treated with rHDL under normal oxygen conditions showed significant increases
in CREBRF (307 ± 36%, Figure 1B) and TRIM2 (286 ± 32%, Figure 1C) mRNA levels compared to
phosphate-buffered saline (PBS) controls (both p < 0.0001). Under hypoxic conditions, there was
also increased expression of CREBRF (243 ± 29%) and TRIM2 (259 ± 35%) following treatment with
rHDL (both p < 0.0001 vs. hypoxia PBS controls). Meanwhile, HCAECs treated with PBS alone had
significantly upregulated CREBRF (132 ± 13%) and TRIM2 (124 ± 4%) mRNA levels in hypoxia
compared to normoxia (p < 0.05 and p < 0.001, respectively). This suggested that rHDL was able
to augment the hypoxia-driven increase in mRNA expression of both CREBRF and TRIM2. In the
absence of an inflammatory stimulus, rHDL also led to upregulation of CREBRF (206± 27%, Figure 1D)
and TRIM2 (163 ± 12%, Figure 1E) mRNA levels relative to PBS controls (p < 0.05 and p < 0.0001,
respectively). Subsequent exposure of HCAECs to TNFα induced a significant increase in CREBRF
mRNA (160 ± 12%) but interestingly, a significant reduction in TRIM2 mRNA (62 ± 3%). rHDL
pre-treatment of TNFα-stimulated HCAECs further increased expression of CREBRF (200 ± 33%)
and was able to rescue the drop in TRIM2 mRNA levels (175 ± 29%) that occurred (p < 0.001 and
p < 0.0001, respectively vs. TNFα PBS control). These findings collectively indicate that rHDL was able
to induce both CREBRF and TRIM2 mRNA expression under basal conditions, however, these effects
were further modulated when cells were exposed to hypoxia and inflammatory stimuli.
Consistent with changes seen with mRNA expression, HCAECs exposed to hypoxic conditions
alone exhibited significantly higher CREBRF (120 ± 8%; Figure 2A) and TRIM2 (149 ± 20%, Figure 2B)
protein levels compared to normoxia controls (both p < 0.05). In normoxia, pre-treatment with rHDL
significantly increased CREBRF protein (160 ± 11%) and TRIM2 protein (184 ± 38%) compared to
pre-treatment with PBS alone (p < 0.01 and p < 0.05 respectively), reflecting a similar trend seen with
mRNA expression. However, the rise in CREBRF protein (126 ± 15%) and TRIM2 protein (122 ± 19%)
following rHDL treatment in hypoxia was not statistically significant.
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Figure 2. CREBRF and TRIM2 protein expression in HCAECs in response to rHDL or PBS treatment
in hypoxia and inflammation, with representative Western blot images. (A) CREBRF protein and (B)
TRIM2 protein in PBS- and rHDL-treated cells exposed to normoxia and hypoxia; (C) CREBRF protein
and (D) TRIM2 protein in PBS- and rHDL-treated cells with and without tumor necrosis factor alpha
(TNFα) stimulation. Results are mean ± SEM. * p < 0.05, ** p < 0.01 by two-way ANOVA with post hoc
analysis using Bonferroni’s multiple comparisons test. ˆ p < 0.05 by unpaired two-tailed t-test.
HCAECs stimulated with TNFα had higher CREBRF (134 ± 14%, Figure 2C) and TRIM2
(125 ± 15%, Figure 2D) protein levels compared to PBS controls, however only the former was
statistically significant (p < 0.05). In the absence of TNFα, pre-treatment with rHDL increased CREBRF
and TRIM2 protein (138 ± 17% and 126 ± 17%, respectively vs. PBS controls), though this did
not reach statistical significance. Following exposure to TNFα, CREBRF and TRIM2 protein levels
were increased in response to rHDL treatment (144 ± 23% and 114 ± 22%, respectively vs. TNFα
PBS controls), however, again this was not significant. These findings collectively imply that rHDL
has more striking effects on CREBRF and TRIM2 expression at the transcriptional rather than the
translational level.
2.3. rHDL Upregulates CREBRF and TRIM2 mRNA Expression in HCAECs Predominantly through PLPC
To determine the forms and components of HDL that may be responsible for the effects on
CREBRF and TRIM2 mRNA expression, HCAECs were treated separately with native HDL, rHDL
and its individual components, apoA-I and PLPC. Consistent with previous findings, treatment with
rHDL significantly increased CREBRF mRNA expression in normoxia and hypoxia (209 ± 20% and
171 ± 17% vs. respective PBS controls, both p < 0.0001, Figure 3A), as well as increasing TRIM2 mRNA
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in normoxia and hypoxia (167 ± 8% and 160 ± 9% vs. respective PBS controls, both p < 0.0001,
Figure 3B). This effect was largely attributable to the PLPC component of rHDL, as treatment with
PLPC alone significantly increased CREBRF mRNA expression in normoxia and hypoxia (168 ± 10%
and 167 ± 11% vs. PBS controls, p < 0.05 and p < 0.0001, respectively), as well as increasing TRIM2
mRNA in hypoxia (146 ± 11% vs. PBS control, p < 0.001). There were no significant differences in
CREBRF or TRIM2 mRNA following treatment with native HDL or apoA-I in normoxia or hypoxia.
Figure 3. CREBRF and TRIM2 mRNA expression in HCAECs following treatment with native HDL,
1-palmitoyl-2-linoleoyl-phosphatidylcholine (PLPC), lipid-free apolipoprotein A-I (apoA-I), rHDL or
PBS in hypoxia and inflammation. (A) CREBRF mRNA and (B) TRIM2 mRNA in cells exposed to
normoxia and hypoxia; (C) CREBRF mRNA and (D) TRIM2 mRNA in cells with and without TNFα
stimulation. mRNA expression was measured by real-time quantitative polymerase chain reaction
(qPCR). Results are mean± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 by two-way ANOVA
with post hoc analysis using Bonferroni’s multiple comparisons test.
Treatment of HCAECs with rHDL increased CREBRF mRNA expression with and without TNFα
(146 ± 8% and 173 ± 5% vs. respective PBS controls, both p < 0.0001, Figure 3C), again consistent with
previous findings. Strikingly however, treatment with the PLPC component of rHDL alone resulted
in increased CREBRF mRNA expression beyond that induced by rHDL, both in the presence and
absence of TNFα (203 ± 13% and 225 ± 15% vs. respective PBS controls, both p < 0.0001). Native
HDL or apoA-I treatment did not alter CREBRF mRNA significantly. Meanwhile, TRIM2 mRNA was
significantly increased in HCAECs in response to PLPC, apoA-I and rHDL (189 ± 21%, 134 ± 7% and
163 ± 15% vs. PBS control with p < 0.0001, p < 0.01 and p < 0.0001, respectively, Figure 3D). In response
to TNFα, a significant global decrease in TRIM2 mRNA was seen (p < 0.001). However, only PLPC and
rHDL treatment rescued this drop in TRIM2 mRNA (154 ± 5% and 148 ± 10% vs. TNFα PBS control
with p < 0.01 and p < 0.05, respectively). Collectively, these findings imply that rHDL modulates
CREBRF and TRIM2 mRNA expression predominantly via PLPC.
Int. J. Mol. Sci. 2018, 19, 1903 7 of 17
2.4. Tubulogenesis is Impaired by Lentiviral Knockdown of TRIM2 in Hypoxia and Inflammation
CREBRF and TRIM2 expression was suppressed by treating HCAECs with short hairpin RNA
(shRNA) delivered using a lentiviral approach. shRNA-mediated knockdown of CREBRF and TRIM2
protein expression was confirmed by Western blotting (Supplementary Figure S1).
Consistent with our previous studies [9,10], we found that hypoxia induces endothelial tubule
formation when compared to the normoxia control (p < 0.05, Figure 4). Under hypoxic conditions,
the extent of tubulogenesis in HCAECs transduced with lentivirus containing shRNA against TRIM2
was significantly reduced (54 ± 9%) compared to cells transduced with shRNA against a random
control sequence (shControl, p < 0.01). HCAECs transduced with lentivirus containing shRNA against
CREBRF also demonstrated reduced tubulogenesis (88 ± 11%) relative to shControl cells, however this
was not statistically significant.
Stimulation with the inflammatory cytokine TNFα promoted tubule formation compared to
non-TNFα-stimulated cells (p < 0.05, Figure 5). Interestingly, TNFα-stimulated tubule formation
was significantly reduced in HCAECs transduced with lentivirus containing shRNA against TRIM2
(59 ± 11%) compared to cells transduced with shControl (p < 0.05). HCAECs transduced with lentivirus
containing shRNA against CREBRF demonstrated marginally reduced tubulogenesis (92 ± 14%)
relative to shControl cells but this was not statistically significant.
Figure 4. Cont.
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Figure 4. Tubulogenesis under hypoxic conditions in HCAECs transduced with lentivirus containing
shRNA against a control sequence (shControl), CREBRF (shCREBRF) or TRIM2 (shTRIM2) compared to
non-transduced HCAECs under normoxic conditions. (A) Representative images of tubule formation
were photographed under light microscopy. Scale bars, 50 µm; (B) Number of tubules was counted
and analyzed using ImageJ software. Results are mean ± SEM. * p < 0.05, ** p < 0.01 by unpaired
two-tailed t-test.
Figure 5. Cont.
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Figure 5. Tubulogenesis following TNFα stimulation in HCAECs transduced with lentivirus
containing shControl, shCREBRF or shTRIM2 compared to non-transduced non-TNFα-stimulated
cells. (A) Representative images of tubule formation were photographed under light microscopy. Scale
bars, 50 µm. (B) Number of tubules was counted and analyzed using ImageJ software. Results are
mean ± SEM. * p < 0.05 by unpaired two-tailed t-test.
2.5. Lentiviral Knockdown of TRIM2 Attenuates the Pro-Angiogenic Action of rHDL in Hypoxia
We next sought to determine whether TRIM2 is important in mediating the angiogenic action
of rHDL. Cells transduced with either shControl or shTRIM2 were treated with PBS or rHDL,
then underwent a Matrigel tubulogenesis assay. We found that rHDL significantly augmented
hypoxia-induced tubule formation in shControl cells (p < 0.05, Figure 6). However, the pro-angiogenic
action of rHDL in hypoxia was attenuated in shTRIM2 cells (p < 0.0001). On the other hand, treatment
with rHDL suppressed TNFα-stimulated tubule formation (p < 0.05, Figure 7), however, interestingly,
TRIM2 knockdown did not inhibit this effect any further.
Figure 6. Cont.
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Figure 6. Tubulogenesis following exposure to hypoxia in HCAECs transduced with lentivirus
containing shControl or shTRIM2 treated with either PBS or rHDL compared to cells under normoxic
conditions. (A) Representative images of tubule formation were photographed under light microscopy.
Scale bars, 50 µm; (B) Number of tubules was counted and analyzed using ImageJ software. Results are
mean ± SEM. * p < 0.05, **** p < 0.0001 by two-way ANOVA with post hoc analysis using Bonferroni’s
multiple comparisons test.
Figure 7. Cont.
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Figure 7. Tubulogenesis following TNFα stimulation in HCAECs transduced with lentivirus
containing shControl or shTRIM2 treated with either PBS or rHDL compared to non-stimulated
cells. (A) Representative images of tubule formation were photographed under light microscopy. Scale
bars, 50 µm; (B) Number of tubules was counted and analyzed using ImageJ software. Results are
mean ± SEM. * p < 0.05, ** p < 0.01 by two-way ANOVA with post hoc analysis using Bonferroni’s
multiple comparisons test.
3. Discussion
The finding that HDLs are able to promote hypoxia-induced physiological angiogenesis yet
inhibit inflammation-driven pathological angiogenesis represents an exciting therapeutic prospect for
a range of angiogenesis-associated diseases. Our current study employed a microarray approach to
screen for novel genes that may regulate angiogenesis downstream of HDL. We identified CREBRF
and TRIM2 as being upregulated by rHDL under both hypoxia and TNFα-induced inflammation.
This finding was supported by measuring mRNA and protein expression of these genes in HCAECs,
though interestingly, the observed changes were much more striking at a transcriptional rather than
translational level. Moreover, the effects appeared to be predominantly attributable to the PLPC
component of rHDL. Knockdown of TRIM2 was found to impair tubulogenesis in vitro particularly
under hypoxic conditions, indicating its potential role in physiological angiogenesis.
To date, relatively little is known about the function of TRIM2 and its role in cardiovascular
biology has not yet been previously explored. TRIM2 encodes the tripartite motif-containing
protein 2, an E3 ubiquitin ligase highly expressed in the central nervous system that functions to
ubiquitinate and target certain proteins for proteasomal degradation [19]. In particular, TRIM2 is
known to target neurofilament light-chain (NF-L), and in doing so, directs neuronal polarization
by allowing the specification of particular neurites to become axons [20]. In a TRIM2-knockout
mouse model, intra-axonal accumulation of NF-L secondary to TRIM2 deficiency caused progressive
neurodegeneration that manifested as juvenile-onset tremor and ataxia [19]. Human case reports have
also described loss-of-function mutations in TRIM2 causing early-onset axonal neuropathies [21,22].
Interestingly, TRIM2 has been found to confer neuroprotection following brief periods of ischemia by
targeting the pro-apoptotic factor Bim for degradation [23]. It is conceivable that TRIM2 may well play
a similar role in mediating the angiogenic response to ischemia downstream of HDL.
By comparison, even less is known about CREBRF, which encodes a regulatory factor for
cyclic adenosine monophosphate (cAMP)-response element binding protein 3 (CREB3). CREBRF
is highly expressed in mouse heart and kidney, and functions as a negative regulator of CREB3,
a transcription factor activated as part of the endoplasmic reticulum (ER) unfolded protein response
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(UPR) [24]. Under conditions of prolonged ER stress, the ER membrane-bound protein CREB3 is
cleaved and translocates to the nucleus where it activates UPR-related target genes. When present,
CREBRF binds and sequesters CREB3 into discrete nuclear sub-regions, suppressing its activity and
promoting its degradation [24]. How this mechanism may be linked to angiogenesis or HDL is unclear,
however the role of ER stress and UPR activation in tumor-related angiogenesis [25,26] and endothelial
dysfunction [27,28] is increasingly being recognized. HDL has been shown to directly inhibit ER stress
induced by oxidized low-density lipoproteins which promote the formation of macrophage-derived
foam cells in atherosclerotic plaque [29,30].
In our current study, there was marked upregulation of both CREBRF and TRIM2 mRNA
secondary to rHDL treatment in HCAECs, validating the findings of the microarray study. This effect
was more related to rHDL itself rather than hypoxia or TNFα stimulation. Interestingly, we observed
that TRIM2 mRNA was reduced in response to TNFα while it was increased in hypoxia independent
of HDL treatment. rHDL treatment subsequently reversed the TNFα-induced drop in TRIM2 mRNA,
while augmenting the rise in TRIM2 mRNA in hypoxia. These dichotomous effects may reflect a role
for TRIM2 as a molecular switch that directs HDL’s actions down distinct angiogenic pathways in a
context-specific manner, though more studies will be required to clarify this effect. It is worth nothing
that native HDLs did not significantly alter mRNA expression of CREBRF or TRIM2 in HCAECs when
compared to PBS, as opposed to the effect of rHDL. This finding is consistent with previous studies of
angiogenesis in both hypoxia and inflammation [9], and likely reflects the heterogeneity of native HDL
particles that have been isolated from multiple human volunteers. These HDL particles may have
also undergone certain chemical and/or compositional modifications in vivo that have rendered them
somewhat dysfunctional. On the other hand, rHDL is synthesized de novo with purified apoA-I and
PLPC; and should therefore have minimal loss of function.
Moreover, by isolating rHDL into its components, our study also demonstrated that PLPC,
as opposed to apoA-I, appeared to be primarily driving the transcriptional upregulation of CREBRF
and TRIM2. Few studies have directly explored which components of HDL may be responsible for its
regulation of angiogenesis. Several studies have shown that apoA-I can modulate physiological and
pathological angiogenesis in vivo [9,31,32] but the effect of phospholipids alone and whether these
activate alternative signalling pathways to apoA-I is unknown. Prosser et al. demonstrated that rHDL
significantly enhances hypoxia-induced tubule formation in HCAECs and increases the expression of
angiogenic mediators HIF-1α and VEGF, but these effects were not seen with lipid-free apoA-I (i.e.,
without PLPC), suggesting a potential role for PLPC [9]. Earlier studies also found that phospholipid
composition significantly alters the ability of rHDL to inhibit TNFα-induced VCAM-1 expression,
finding PLPC was particularly potent in its anti-inflammatory effect compared to other phospholipid
species [33]. In our study, the ability of PLPC vesicles to induce CREBRF mRNA expression beyond
that of rHDL under inflammatory conditions was surprising. This was, however, an isolated finding
not seen under hypoxic conditions or with TRIM2 mRNA expression. Moreover, previous studies
by our group have found that PLPC vesicles alone do not augment tubulogenesis in HCAECs [10],
implying that while it is interesting that PLPC upregulated CREBRF and TRIM2 mRNA expression,
this may not translate to a functional angiogenic response.
Though we observed marked changes in CREBRF and TRIM2 mRNA in response to rHDL,
these changes were generally not translated to significant changes in protein expression. This may
reflect the presence of additional aspects of post-transcriptional regulation that have yet to be
characterized. One example is the finding that TRIM2 is a target of non-coding microRNA-181c [34],
which has been implicated in cancer signalling [35–37]. A recent in vivo study also demonstrated that
microRNA-181c, through its modulation of TRIM2, can attenuate cognitive impairment in rats induced
by chronic cerebral ischemia [38]. In the case of CREBRF, the rapid turnover of CREBRF protein, with a
reported half-life of less than 20 min [24], may also account for the lack of changes seen at the protein
level. Further studies will be needed to elucidate whether microRNAs or other post-transcriptional or
Int. J. Mol. Sci. 2018, 19, 1903 13 of 17
post-translational mechanisms significantly alter the expression of these genes, and whether changes
in mRNA levels alone are sufficient to affect cellular signalling and functional angiogenesis.
In line with this, we assessed the effect of CREBRF and TRIM2 knockdown on angiogenesis
in vitro using a well-validated tubulogenesis assay. shRNA knockdown of CREBRF did not produce
any significant inhibition of tubulogenesis, suggesting that CREBRF may not play a critical role in
angiogenesis despite being transcriptionally upregulated in response to rHDL under both conditions.
However, TRIM2-deficient HCAECs had significantly impaired tubulogenesis in both hypoxic
and inflammatory conditions, suggesting that TRIM2 is more important for angiogenic function.
Furthermore, we find that knockdown of TRIM2 attenuated the ability of rHDL to augment tubule
formation in hypoxia. However, TRIM2 knockdown did not have any further additional benefits to
the anti-angiogenic action of rHDL under inflammatory conditions. This demonstrates that TRIM2
may be a novel regulator of the pro-angiogenic action of rHDL in hypoxia.
4. Materials and Methods
4.1. Preparation of Native HDL, Discoidal rHDL, ApoA-I, and Phospholipid Vesicles
Native HDLs were isolated from pooled samples of normal human plasma (5 donors, Red Cross
Blood Service, Alexandria, NSW, Australia). The HDL fraction (1.063–1.210 g/mL) was isolated
by ultracentrifugation followed by dialysis against phosphate-buffered saline. ApoA-I was further
isolated from delipidated HDL by anion-exchange chromatography. rHDL was prepared from purified
apoA-I complexed with PLPC using the cholate dialysis method at an initial PLPC:apoA-I molar ratio
of 100:1. The final PLPC:apoA-I molar ratio was 80–100:1. PLPC vesicles were prepared by sonication
(3 cycles of 5 min each on ice) in PBS and cholate then dialysed against PBS. The protein concentration
of apoA-I was determined using the bicinchoninic acid (BCA) assay (ThermoFisher Scientific, Scoresby,
VIC, Australia), and phospholipid concentrations were determined enzymatically (Wako, Richmond,
VA, USA).
4.2. Microarray
GeneChip® PrimeViewTM Human Gene Expression Arrays were purchased from Affymetrix,
Inc. (Santa Clara, CA, USA). Human microvascular endothelial cells (HMVECs, Cell Applications,
San Diego, CA, USA) were cultured and used at passage 5. They were seeded at a density of
8 × 104 cells/well and 1.5× 105 cells/well for the hypoxia and inflammation experiments respectively,
then pre-incubated for 24 h with either PBS or rHDL (20 µM, final apoA-I concentration). Cells
were exposed to hypoxia (1.2% O2 balanced with N2) for 8 h or the inflammatory cytokine TNFα
(0.6 ng/mL) for 4.5 h. Total RNA was extracted as outlined below. The GeneChip® 3′ IVT PLUS
Reagent Kit (Affymetrix, Inc., Santa Clara, CA, USA) was then used to prepare targets for the arrays.
Poly-A RNA control stock was diluted 1:200,000 then added to 250 ng total RNA. This was reverse
transcribed into first strand complementary DNA (cDNA) in an Eppendorf® Mastercycler, followed
by second strand cDNA synthesis. Biotin-labelled amplified RNA (aRNA) was generated by in vitro
transcription following incubation for 16 h. aRNA was purified on a magnetic plate using aRNA
Binding Mix containing magnetic beads, then quantified using a NanoDrop spectrophotometer.
12 µg aRNA was taken to undergo fragmentation, followed by quality assessment using a Bio-Rad
Experion electrophoresis system. 10 µg of fragmented aRNA underwent hybridization to the array for
16.5 h in a GeneChip® Hybridization Oven 645 (Affymetrix), followed by washing and staining on a
GeneChip® Fluidics Station 450 (Affymetrix). The arrays were scanned using a GeneChip® Scanner
3000 7G (Affymetrix), then results were analyzed by the Bioinformatics Lab, Centenary Institute,
NSW, Australia.
Int. J. Mol. Sci. 2018, 19, 1903 14 of 17
4.3. Cell Culture
Human coronary artery endothelial cells (Cell Applications, San Diego, CA, USA) were cultured
in MesoEndo medium (Cell Applications) and used at passages 3–4. HCAECs were then trypsinized,
counted and seeded at a density of 8 × 104 cells/well and 1.5 × 105 cells/well for the hypoxia
and inflammation experiments, respectively, and cultured at 37 ◦C in 5% CO2. HCAECs were then
pre-incubated for 24 h with either PBS (vehicle control) or rHDL comprised of apoA-I complexed with
PLPC at a final apoA-I concentration of 20 µM. Following incubation, cells were washed with PBS and
replaced with fresh MesoEndo media. The cells were then exposed to an angiogenic stimulus, either
by incubation for 8 h at 5% CO2 and 1.2% O2 balanced with N2 (to mimic hypoxia), or by treatment
with TNFα (0.6 ng/mL) for 4.5 h (to mimic inflammation). Each experiment was performed at least six
times independently with duplicates or triplicates for each condition.
To investigate the effect of various components of HDL, HCAECs were cultured in MesoEndo
media as described above. HCAECs were pre-incubated for 16 h with either PBS control or rHDL,
apoA-I, native HDL (all 20 µM final apoA-I concentration) or PLPC vesicles (2 mM). The cells were
then exposed to hypoxia or TNFα as described above. Each experiment was performed at least three
times independently with duplicates or triplicates for each condition.
4.4. mRNA Expression
To measure mRNA expression, total RNA was extracted with TRI reagent and the amount
quantitated using a NanoDrop spectrophotometer. Absorbance was measured at 260 and 280 nm,
and the purity was determined from the absorbance ratio (A260/A280). 200 ng of total RNA
was reverse transcribed in triplicate using the iScript cDNA synthesis kit (Bio-Rad Laboratories,
Hercules, CA, USA). The expression of TRIM2 and CREBRF was measured by real-time PCR
using SYBR Green fluorophore in a Bio-Rad Cfx96 thermocycler. All amplicons were amplified
using iQ SYBR Green Supermix (Bio-Rad Laboratories), and 20 pmol each of forward and reverse
primers for TRIM2 (F: 5′-ATCCGATCCGCTGATGTGTC-3′; R: 5′-TGTACATGCTTGCGGGTCTT-3′),
CREBRF (F: 5′-GGAAGGTCCTGGGTCACTTG-3′; R: 5′-TGGCTGTTCACCCAAGTTGT-3′) and
β2-microglobulin (B2M) as the reference housekeeper gene (F: 5′-CATCCAGCGTACTCCAAAGA-3′;
R: 5′-GACAAGTCTGAATGCTCCAC-3′). Relative changes in mRNA expression were calculated using
the ∆∆Ct method, normalized to B2M.
4.5. Protein Expression
To measure protein expression, cells were lysed with radioimmunoprecipitation assay lysis buffer
(20 mM Tris-HCl, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl
fluoride, 1.5 µg/mL aprotinin, 1 µg/mL leupeptin, 1 µg/mL pepstatin, 1 mM sodium orthovanadate,
and 0.2% Triton X-100; pH 7.4). Protein concentrations were determined using the bicinchoninic assay
(BCA), and 8 µg of the protein extracts were loaded for Western blot analysis. These were probed
with antibodies for CREBRF (sc-133747, 1:200; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA),
TRIM2 (ab123899, 1:500; Abcam, Cambridge, UK) and α-tubulin (ab40742, 1:5000; Abcam, Cambridge,
UK), used to confirm equal protein loading. Protein levels were quantified from digitized images of
the nitrocellulose membranes using Bio-Rad ImageLab software (Bio-Rad Laboratories).
4.6. Lentiviral shRNA Knockdown of CREBRF and TRIM2—Matrigel Tubulogenesis Assay
HCAECs were seeded at 5 × 104 cells/well and cultured at 37 ◦C in 5% CO2. HCAECs were
then exposed for 24 h to either PBS (non-transduced control) or 1 × 104 infectious units (IFU)/mL
of lentiviral particles containing shRNA directed against CREBRF, TRIM2 or a control sequence in
the presence of polybrene (8 µg/mL). After lentiviral transduction, the virus-containing media was
removed and replaced with fresh MesoEndo media for 72 h. Matrigel tubulogenesis assays were used
to assess the effect of CREBRF and TRIM2 knockdown. Transduced HCAECs were trypsinized, counted
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and seeded at a density of 1.2 × 104 cells/well onto growth factor-reduced Matrigel matrix, phenol
red-free (40 µL; Becton Dickinson, Franklin Lakes, NJ, USA) that had been polymerized for 30 min at
37 ◦C. Cells were incubated for 4 h under normoxic or hypoxic conditions (1.2% O2 as above), or with
TNFα (0.5 ng/mL) to mimic inflammatory conditions. In parallel experiments, HCAECs transduced
with either shControl or shTRIM2 were treated with either PBS or rHDL for 16 h prior to Matrigel
tubulogenesis assay. Tubules were photographed at x4 magnification under light microscopy and
analyzed using ImageJ (U.S. National Institutes of Health, Bethesda, MD, USA) by counting the total
number of tubules formed. This assay was undertaken twice, with four replicates for each condition.
4.7. Statistical Analyses
Values are expressed as the mean ± SEM. Differences between treatment groups were analyzed
using either an unpaired two-tailed t-test or one-way ANOVA, or for grouped treatments, a two-way
ANOVA was employed followed by post hoc analysis using Bonferroni’s multiple comparisons test.
Significance was set at a value of p < 0.05.
5. Conclusions
Our current study has identified, for the first time, two novel genes CREBRF and TRIM2 that are
transcriptionally upregulated by rHDL, particularly through its PLPC component. TRIM2 appears to
play a critical role in angiogenesis secondary to both hypoxia and inflammation, though further in vivo
studies will be needed to clarify this. Furthermore, TRIM2 knockdown attenuated rHDL-induced
tubule formation in hypoxia, suggesting that it is important in mediating the pro-angiogenic action of
rHDL under physiological conditions. Characterization of such novel regulators of angiogenesis may
hold the key to developing more effective targeted therapies for angiogenesis-related diseases and
may help to better understand the multifunctional modulation of these by HDL.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/19/7/
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